Participants will receive GSK3915393 dose level X twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and PK data from Part A.

Participants will receive placebo matching GSK3915393 dose level X during Part B of the study.

Participants will receive GSK3915393 dose level Y twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and PK data from Part A and Part B.

Participants will receive placebo matching GSK3915393 dose level Y twice daily during Part B of the study

Participants will receive GSK3915393 dose level Z twice daily during Part B of the study. Dose levels will be determined based on safety, tolerability and PK data from Part A and Part B.

Participants will receive placebo matching GSK3915393 dose level Z twice daily during Part B of the study.

Participants will receive GSK3915393 IV microdose in period 1 followed by combination of GSK3915393 IV microdose and itraconazole (ITZ) in period 2. Participants will then receive oral GSK3915393 plus water in period 3, oral GSK3915393 plus grape fruit juice (GFJ) in period 4 and oral GSK3915393 plus ITZ in period 5.

Participants will receive GSK3915393 IV microdose in period 1 followed by combination of GSK3915393 IV microdose and ITZ in period 2. Participants will then receive oral GSK3915393 plus GFJ in period 3, oral GSK3915393 plus water in period 4 and oral GSK3915393 plus ITZ in period 5.

GSK3915393 solution for infusion will be administered intravenously.

Placebo matching GSK3915393 capsules will be given orally.

Participants will be administered with GSK3915393 along with ITZ orally

Participants will be administered with GSK3915393 along with water orally

Participants will be administered with GSK3915393 along with GFJ orally

Blood samples were collected for analysis of chemistry parameters. PCI ranges were >=2*Upper limit of normal (ULN) units per liter (U/L)(Alanine Aminotransferase [ALT]), >=2*ULN (U/L) (Aspartate Aminotransferase ([AST]), >=2*ULN (Alkaline Phosphatase [ALP]) (U/L), >=1.5*ULN (micromoles per liter) (bilirubin), <2 or >2.75 millimoles/liter (L) (mmol/L)(calcium), <3 or >11 mmol/L (glucose), <3 or >5.5 mmol/L (potassium), <130 or >150 mmol/L (sodium),<50 or >85 grams/liter (protein). Participants were counted in worst case category that their value changes to (low, within [w/in] range or no change [NC], or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, are recorded in 'To within Range No Change' category. Participants were counted twice if participant had values that changed 'To Low' and 'To High', so percentages may not add to 100 percentage (%).

Blood samples were collected for analysis of creatinine. Participants were counted under increase of PCI if they had change from Baseline > 44.2 micromoles per Liter for any post Baseline assessment. Participants who did not meet this PCI criteria are counted as within (w/in) range.

Blood samples were collected for analysis of chemistry parameters. PCI range for Urea: High >10.5 mmol/L. Participants were counted in worst case category that their value changes to (within [w/in] range or no change [NC], or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, are recorded in 'To within Range No Change' category.

Blood samples were collected for analysis of hematology parameters. PCI ranges were >1*10^9 cell per liter (cells/L) (eosinophils), <0.2 or >0.54 proportion of red blood cells in blood (hematocrit), <80 or >180 grams per liter(g/L) (hemoglobin), <3 or >20 x10^9 cells/L (leukocytes), <0.8*10^9 cells/L (lymphocytes), <1.5 or >16*10^9 cells/L (neutrophils) and <100 or >550*10^9 cells/L (platelets). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (for example [e.g.], High to High), or whose value became within range, were recorded in "To within Range or No Change" category. Participants were counted twice if participant has values that changed 'To Low' & 'To High', so the percentages may not add to 100%.

Vital signs included diastolic blood pressure (DBP), systolic blood pressure (SBP), pulse rate (PR), body temperature, respiratory rate (RR) and were measured after resting for at least 5 minutes in semi-supine position. PCI ranges were, SBP (millimeters of mercury[mmHg]): <85 (low) or >160 (high), DBP (mmHg): <45 (low) or >100 (high), heart rate (beats per minute): <40 (low) or >110 (high), respiration rate (breaths per minute):<=8 (low) or >20 (high) and body temperature (degrees Celsius) <=35.5 (low) or >38.0 (high). Participants were counted in worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, are recorded in 'To W/in Range No Change' category. Participants were counted twice if participant had values that changed 'To Low' and 'To High', so percentages may not add to 100%.

Twelve lead ECG was obtained using an ECG machine that automatically calculated the heart rate and measured QTc, PR, QRS intervals. Abnormal findings were categorized as clinically significant and not clinically significant. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline abnormal ECG findings have been presented.

A full physical examination was performed which included, at a minimum, assessments of the Skin, Cardiovascular, Respiratory, Gastrointestinal and Neurological systems.

Blood samples were collected for analysis of chemistry parameters. PCI ranges were >=2*ULN (U/L)(ALT), >=2*ULN (U/L) (AST), >=2*ULN (ALP) (U/L), >=1.5*ULN (micromoles per liter) (bilirubin), <2 or >2.75 millimoles/liter (L) (mmol/L)(calcium), <3 or >11 mmol/L (glucose), <3 or >5.5 mmol/L (potassium), <130 or >150 mmol/L (sodium),<50 or >85 grams/liter (protein). Participants were counted in worst case category that their value changes to (low, within [w/in] range or no change [NC], or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, are recorded in 'To within Range No Change' category. Participants were counted twice if participant had values that changed 'To Low' and 'To High', so percentages may not add to 100 percentage (%).

Blood samples were collected for analysis of chemistry parameters. PCI range for Urea: High >10.5 mmol/L. Participants were counted in worst case category that their value changes to (within [w/in] range or NC, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, are recorded in 'To within Range No Change' category.

Blood samples were collected for analysis of creatinine. Participants were counted under increase of PCI if they had change from Baseline > 44.2 micromoles per Liter for any post Baseline assessment. Participants who did not meet this PCI criteria are counted as w/in range. Participants whose laboratory value became within range, were recorded in 'To within Range' category.

Blood samples were collected for analysis of hematology parameters. PCI ranges were 1*10^9 cell per liter (cells/L) (eosinophils), <0.2 or >0.54 proportion of red blood cells in blood (hematocrit), <80 or >180 grams per liter(g/L) (hemoglobin), <3 or >20 x10^9 cells/L (leukocytes), <0.8*10^9 cells/L (lymphocytes), <1.5 or >16*10^9 cells/L (neutrophils) and <100 or >550*10^9 cells/L (platelets). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (for example [e.g.], High to High), or whose value became within range, were recorded in "To within Range or No Change" category. Participants were counted twice if participant has values that changed 'To Low' & 'To High', so the percentages may not add to 100%.

Vital signs included DBP, SBP, PR, body temperature, RR and were measured after resting for at least 5 minutes in semi-supine position. PCI ranges were, SBP (mmHg): <85 (low) or >160 (high), DBP (mmHg): <45 (low) or >100 (high), heart rate (beats per minute): <40 (low) or >110 (high), respiration rate (breaths per minute):<=8 (low) or >20 (high) and body temperature (degrees Celsius) <=35.5 (low) or >38.0 (high). Participants were counted in worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, are recorded in 'To W/in Range No Change' category. Participants were counted twice if participant had values that changed 'To Low' and 'To High', so percentages may not add to 100%.

Twelve lead ECG was obtained using an ECG machine that automatically calculated the heart rate and measured QTc, PR, QRS intervals. Abnormal findings were categorized as clinically significant and not clinically significant. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline abnormal ECG findings have been presented.

A full physical examination was performed which included, at a minimum, assessments of the Skin, Cardiovascular, Respiratory, Gastrointestinal and Neurological systems.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393. For Part C: GSK3915393 20 mg+ Water and Part C: GSK3915393 20 mg+ GFJ, concentrations after 24 hours post-dose were expected to be non-quantifiable. Cmax was derived based on collected assessments (up to 24 hours for Part C: GSK3915393 20 mg+ Water and Part C: GSK3915393 20 mg+ GFJ, up to 60 hours for Part C: GSK3915393 20 mg+ ITZ). Only the quantifiable concentration time points were to be considered for assessment of pharmacokinetic parameters.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393. For Part C: GSK3915393 20 mg+ Water and Part C: GSK3915393 20 mg+ GFJ, concentrations after 24 hours post-dose were expected to be non-quantifiable. Tmax was derived based on collected assessments (up to 24 hours for Part C: GSK3915393 20 mg+ Water and Part C: GSK3915393 20 mg+ GFJ, up to 60 hours for Part C: GSK3915393 20 mg+ ITZ). Only the quantifiable concentration time points were to be considered for assessment of pharmacokinetic parameters.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393. For Part C: GSK3915393 20 mg+ Water and Part C: GSK3915393 20 mg+ GFJ, concentrations after 24 hours post-dose were expected to be non-quantifiable. AUC(0-inf) was derived based on collected assessments (up to 24 hours for Part C: GSK3915393 20 mg+ Water and Part C: GSK3915393 20 mg+ GFJ, up to 60 hours for Part C: GSK3915393 20 mg+ ITZ). Only the quantifiable concentration time points were to be considered for assessment of pharmacokinetic parameters.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393. For Part C: GSK3915393 20 mg+ Water and Part C: GSK3915393 20 mg+ GFJ, concentrations after 24 hours post-dose were expected to be non-quantifiable. t1/2 was derived based on collected assessments (up to 24 hours for Part C: GSK3915393 20 mg+ Water and Part C: GSK3915393 20 mg+ GFJ, up to 60 hours for Part C: GSK3915393 20 mg+ ITZ). Only the quantifiable concentration time points were to be considered for assessment of pharmacokinetic parameters.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393. Absolute bioavailability is the amount of drug from a formulation that reaches the systemic circulation relative to an IV dose. It was expressed as ratio was calculated as (AUC[0-inf] for oral divided by oral dose) divided by (AUC[0-inf] for IV/dose given as IV).

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393. FH was expressed as ratio and was calculated as: 1 minus hepatic extraction ratio. Hepatic extraction ratio=hepatic blood clearance (milliliters per minute)/hepatic blood flow (milliliters per minute).

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393. Product of FA*FG was calculated as: (absolute bioavailability [F] divided by fraction of drug escaping hepatic metabolism [FH]).

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAE is defined as any serious adverse event that, at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per investigator's medical or scientific judgment.

Blood samples were collected for analysis of chemistry parameters. PCI ranges were >=2*ULN (U/L)(ALT), >=2*ULN (U/L) (AST), >=2*ULN (ALP) (U/L), >=1.5*ULN (micromoles per liter) (bilirubin), <2 or >2.75 millimoles/liter (L) (mmol/L)(calcium), <3 or >11 mmol/L (glucose), <3 or >5.5 mmol/L (potassium), <130 or >150 mmol/L (sodium),<50 or >85 grams/liter (protein). Participants were counted in worst case category that their value changes to (low, within [w/in] range or no change [NC], or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, are recorded in 'To within Range No Change' category. Participants were counted twice if participant had values that changed 'To Low' and 'To High', so percentages may not add to 100 percentage (%).

Blood samples were collected for analysis of creatinine. Participants were counted under increase of PCI if they had change from Baseline >44.2 micromoles per Liter for any post Baseline assessment. Participants who did not meet this PCI criteria are counted as w/in range.

Blood samples were collected for analysis of chemistry parameters. PCI range for Urea: High >10.5 mmol/L. Participants were counted in worst case category that their value changes to (within [w/in] range or no change [NC], or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, are recorded in 'To within Range No Change' category.

Blood samples were collected for analysis of hematology parameters. PCI ranges were >1*10^9 cell per liter (cells/L) (eosinophils), <0.2 or >0.54 proportion of red blood cells in blood (hematocrit), <80 or >180 grams per liter(g/L) (hemoglobin), <3 or >20 x10^9 cells/L (leukocytes), <0.8*10^9 cells/L (lymphocytes), <1.5 or >16*10^9 cells/L (neutrophils) and <100 or >550*10^9 cells/L (platelets). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (for example [e.g.], High to High), or whose value became within range, were recorded in "To within Range or No Change" category. Participants were counted twice if participant has values that changed 'To Low' & 'To High', so the percentages may not add to 100%.

Vital signs included DBP, SBP, PR, body temperature, RR and were measured after resting for at least 5 minutes in semi-supine position. PCI ranges were, SBP (mmHg): <85 (low) or >160 (high), DBP (mmHg): <45 (low) or >100 (high), heart rate (beats per minute): <40 (low) or >110 (high), respiration rate (breaths per minute):<=8 (low) or >20 (high) and body temperature (degrees Celsius) <=35.5 (low) or >38.0 (high). Participants were counted in worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, are recorded in 'To W/in Range No Change' category. Participants were counted twice if participant had values that changed 'To Low' and 'To High', so percentages may not add to 100%.

Twelve lead ECG was obtained using an ECG machine that automatically calculated the heart rate and measured QTc, PR, QRS intervals. Abnormal findings were categorized as clinically significant and not clinically significant. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline abnormal ECG findings have been presented.

A full physical examination was performed which included, at a minimum, assessments of the Skin, Cardiovascular, Respiratory, Gastrointestinal and Neurological systems.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAE is defined as any serious adverse event that, at any dose which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations as per investigator's medical or scientific judgment.

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with treatment related AEs are presented.

Blood samples were collected for analysis of chemistry parameters. PCI ranges were >=2*ULN (U/L)(ALT), >=2*ULN (U/L) (AST), >=2*ULN (ALP) (U/L), >=1.5*ULN (micromoles per liter) (bilirubin), <2 or >2.75 millimoles/liter (L) (mmol/L)(calcium), <3 or >11 mmol/L (glucose), <3 or >5.5 mmol/L (potassium), <130 or >150 mmol/L (sodium),<50 or >85 grams/liter (protein). Participants were counted in worst case category that their value changes to (low, within [w/in] range or no change [NC], or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, are recorded in 'To within Range No Change' category. Participants were counted twice if participant had values that changed 'To Low' and 'To High', so percentages may not add to 100 percentage (%).

Blood samples were collected for analysis of creatinine. Participants were counted under increase of PCI if they had change from Baseline > 44.2 micromoles per Liter for any post Baseline assessment. Participants who did not meet this PCI criteria are counted as w/in range. Participants whose laboratory value became within range, were recorded in 'To within Range' category.

Blood samples were collected for analysis of chemistry parameters. PCI range for Urea: High >10.5 mmol/L. Participants were counted in worst case category that their value changes to ( within [w/in] range or no change [NC], or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, are recorded in 'To within Range No Change' category.

Blood samples were collected for analysis of hematology parameters. PCI ranges were 1*10^9 cell per liter (cells/L) (eosinophils), <0.2 or >0.54 proportion of red blood cells in blood (hematocrit), <80 or >180 grams per liter(g/L) (hemoglobin), <3 or >20 x10^9 cells/L (leukocytes), <0.8*10^9 cells/L (lymphocytes), <1.5 or >16*10^9 cells/L (neutrophils) and <100 or >550*10^9 cells/L (platelets). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (for example [e.g.], High to High), or whose value became within range, were recorded in "To within Range or No Change" category. Participants were counted twice if participant has values that changed 'To Low' & 'To High', so the percentages may not add to 100%.

Vital signs included DBP, SBP, PR, body temperature, RR and were measured after resting for at least 5 minutes in semi-supine position. PCI ranges were, SBP (mmHg): <85 (low) or >160 (high), DBP (mmHg): <45 (low) or >100 (high), heart rate (beats per minute): <40 (low) or >110 (high), respiration rate (breaths per minute):<=8 (low) or >20 (high) and body temperature (degrees Celsius) <=35.5 (low) or >38.0 (high). Participants were counted in worst case category that their value changes to (low, within range or no change, or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, are recorded in 'To W/in Range No Change' category. Participants were counted twice if participant had values that changed 'To Low' and 'To High', so percentages may not add to 100%.

Twelve lead ECG was obtained using an ECG machine that automatically calculated the heart rate and measured QTc, PR, QRS intervals. Abnormal findings were categorized as clinically significant and not clinically significant. Clinically significant abnormal findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition. Data for number of participants with worst case post-Baseline abnormal ECG findings have been presented.

A full physical examination was performed which included, at a minimum, assessments of the Skin, Cardiovascular, Respiratory, Gastrointestinal and Neurological systems.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393. FH was expressed as ratio and was calculated as: 1 minus hepatic extraction ratio. Hepatic extraction ratio=hepatic blood clearance (milliliters per minute)/hepatic blood flow (milliliters per minute)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393. FH was expressed as ratio and was calculated as: 1 minus Hepatic extraction ratio. Hepatic extraction ratio=hepatic blood clearance (milliliters per minute)/hepatic blood flow (milliliters per minute)

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393. FG was expressed as ratio and calculated as: AUC of GSK3915393+water divided by AUC of GSK3915393+GFJ.

Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK3915393. FA was expressed as ratio was calculated as absolute bioavailability (F) divided by the product of fraction of drug escaping hepatic metabolism (FH) and fraction of drug escaping gut metabolism (FG).

Participants in Part A received a single oral dose of GSK3915393 15 mg on Day 1 in treatment Period 1; followed by a single oral dose of placebo on Day 1 in treatment Period 2; followed by a single dose of GSK3915393 100 mcg IV on Day 1 in treatment Period 3; further followed by a single oral dose of GSK3915393 160mg on Day 1 in treatment Period 4. Participants were dose in the fed state. There was a washout period of 20 days between periods 1 and 2, washout period between treatment 2 and 3 was of 12 days, washout period between treatment periods 3 and 4 was of 20 days. There was a follow-up period of 14 days.

Participants in Part A received a single oral dose of GSK3915393 15 mg on Day 1 in treatment Period 1; followed by a single oral dose of GSK3915393 60 mg on Day 1 in treatment Period 2; followed by a single dose of GSK3915393 100 mcg IV on Day 1 in treatment Period 3; further followed by a single oral dose of placebo on Day 1 in treatment Period 4. Participants were dosed in fed state. There was a washout period of 20 days between Periods 1 and 2, washout period between treatment 2 and 3 was of 12 days, washout period between treatment periods 3 and 4 was of 20 days. There was a follow-up period of 14 days.

Participants in Part A received a single oral dose of GSK3915393 15 mg on Day 1 in treatment Period 1; followed by a single oral dose of GSK3915393 60 mg on Day 1 in treatment Period 2; followed by a single dose of GSK3915393 100 mcg IV on Day 1 in treatment Period 3; further followed by a single oral dose of GSK3915393 160 mg on Day 1 in treatment Period 4. Participants were dosed in fed state. There was a washout period of 20 days between Period 1 and 2, washout period between treatment 2 and 3 was of 12 days, washout period between treatment period 3 and 4 was of 20 days. There was follow-up period of 14 days.

Participants received placebo matching with GSK3915393 as repeat oral dose for 14 days (dosing frequency twice a day [BID] or QD, matched to the frequency of dosing in the concurrent active treatment arm). The impact of food effect on pharmacokinetic (PK) of GSK3915393 was investigated following Ante-Meridiem (AM) dose on three days in all cohort (Day 3=fasted, Day 5= high fat breakfast, Day 7=standard breakfast).

Participants received GSK3915393 20 mg BID as repeat oral dose for 14 days. The impact of food effect on PK of GSK3915393 was investigated following AM dose on three days in all cohort (Day 3=fasted, Day 5= high fat breakfast, Day 7=standard breakfast).

Participants received GSK3915393 80 mg BID as repeat oral dose for 14 days. The impact of food effect on PK of GSK3915393 was investigated following AM dose on three days in all cohort (Day 3=fasted, Day 5= high fat breakfast, Day 7=standard breakfast).

Participants received GSK3915393 160 mg QD as repeat oral dose for 14 days. The impact of food effect on PK of GSK3915393 was investigated following AM dose on three days in all cohort (Day 3=fasted, Day 5= high fat breakfast, Day 7=standard breakfast).

Participants in Part C received a single dose of GSK3915393 100 mcg IV on Day 1 in treatment Period 1; followed by a single dose of GSK3915393 100mcg IV along with Itraconazole (ITZ) on Day 1 in treatment Period 2; followed by a single oral dose of GSK3915393 20 mg along with grapefruit juice (GFJ) on Day 1 in treatment Period 3; followed by a single oral dose of GSK3915393 20mg along with water (WTR) on Day 1 in treatment Period 4; further followed by a single oral dose of GSK3915393 20 mg along with ITZ in treatment Period 5. There was a washout period of 6 days between treatment Periods 1 and 2, washout period of 24 days between treatment periods 2 and 3, washout period of 10 days between treatment periods 3 and 4 and washout period of 13 days between treatment periods 4 and 5. There was a follow-up of 14 days.

Participants in Part C received a single dose of GSK3915393 100 mcg IV on Day 1 in treatment Period 1; followed by a single dose of GSK3915393 100 mcg IV along with ITZ on Day 1 in treatment Period 2; followed by a single oral dose of GSK3915393 20 mg+ water on Day 1 in treatment Period 3; followed by a single oral dose of GSK3915393 20mg along with GFJ on Day 1 in treatment Period 4; further followed by a single oral dose of GSK3915393 20 mg along with ITZ in treatment Period 5. There was a washout period of 6 days between treatment Periods 1 and 2, washout period of 24 days between treatment periods 2 and 3, washout period of 10 days between treatment periods 3 and 4 and washout period of 13 days between treatment periods 4 and 5. There was a follow-up of 14 days.